How to Get Zetia (Ezetimibe) in Tennessee

What Is Ezetimibe and Why Do Tennessee Patients Need It?

Ezetimibe blocks the NPC1L1 cholesterol transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50% without affecting fat-soluble vitamin absorption [1]. Added to a statin, it lowers LDL-C by an additional 18, 20 percentage points [2]. For Tennessee patients who cannot tolerate high-dose statins, or whose LDL remains above goal on statin monotherapy, ezetimibe fills a real clinical gap.

Tennessee's cardiovascular disease burden makes this relevant. The CDC reports that Tennessee consistently ranks among the top ten states for cardiovascular disease mortality, with age-adjusted heart disease death rates exceeding 230 per 100,000 population [3]. Elevated LDL-C is one of the most modifiable contributors to that burden.

The landmark IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of cardiovascular death, nonfatal MI, unstable angina, coronary revascularization, or nonfatal stroke by 6.4% (absolute risk reduction 2.0 percentage points, NNT 50 over 7 years, P<0.016) compared with simvastatin alone [4]. The American College of Cardiology and American Heart Association cite IMPROVE-IT as the evidence base for their Class IIa recommendation to add ezetimibe in high-risk patients who do not reach LDL-C goals on maximally tolerated statin therapy [5].

Ezetimibe received FDA approval in October 2002 under the brand name Zetia, manufactured by Merck. Generic ezetimibe became available in 2017 [6]. The two are therapeutically interchangeable, and most Tennessee pharmacists will dispense the generic unless "dispense as written" appears on the prescription.

Who Can Prescribe Zetia in Tennessee?

Any licensed prescriber with Tennessee DEA registration or Tennessee prescriptive authority can write for ezetimibe. That includes MDs, DOs, nurse practitioners, and physician assistants.

Tennessee expanded NP prescriptive authority significantly under Tennessee Code Annotated Section 63-7-123, amended in 2023. Nurse practitioners with at least one year of supervised practice can now prescribe Schedule III, V controlled substances and all non-controlled medications, including ezetimibe, without a collaborative practice agreement [7]. PAs in Tennessee prescribe under a supervision agreement with a supervising physician, but ezetimibe as a non-controlled drug requires no special delegation language beyond standard PA prescriptive authority [8].

Telehealth prescribers holding a Tennessee license or a multi-state compact license may prescribe ezetimibe after a synchronous audio-visual visit that meets Tennessee's telehealth standards, codified at Tenn. Code Ann. 63-1-155. The Tennessee Department of Health clarified in 2022 that a prior in-person relationship is not required for non-controlled medication prescribing via telehealth, which means a first telehealth visit can result in a same-day ezetimibe prescription [9].

How to Get a Zetia Prescription in Tennessee: Step-by-Step

Getting ezetimibe in Tennessee follows a short, predictable sequence. The path differs only slightly between telehealth and in-person routes.

Step 1. Get a fasting lipid panel. Most prescribers will want a lipid panel drawn within the past 12 months, and ideally within three months if your LDL management has changed recently. Some telehealth platforms accept a recent lab result uploaded by the patient. Quest Diagnostics and LabCorp both operate draw sites across Tennessee, including Memphis, Nashville, Knoxville, and Chattanooga, often with results in 24 to 48 hours [10].

Step 2. Schedule your visit. An in-person appointment with a primary care physician, cardiologist, or endocrinologist works. Telehealth platforms licensed in Tennessee can often schedule within 24 to 72 hours. During the visit, your provider will review your lipid panel, calculate your 10-year ASCVD risk using the Pooled Cohort Equations endorsed by the ACC/AHA 2019 guideline [5], and determine whether ezetimibe is appropriate.

Step 3. The prescription is sent to your pharmacy. Tennessee law allows electronic prescribing for all non-controlled drugs. Most prescribers send the prescription electronically, and most major chains (CVS, Walgreens, Kroger Pharmacy, Walmart Pharmacy, Publix) stock generic ezetimibe.

Step 4. Handle prior authorization if your insurer requires it. (See the section below for a full breakdown.)

Step 5. Pick up or receive your medication. In-person pharmacy pickup is same-day once the script is on file. Mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) typically deliver within two to five business days for Tennessee addresses.

What Labs Are Needed Before Starting Ezetimibe?

Your prescriber will order a fasting lipid panel as the baseline requirement. Ezetimibe itself has no direct hepatotoxic mechanism, but because it is frequently co-prescribed with a statin, most clinicians also check AST, ALT, and a basic metabolic panel before starting combination therapy [11]. If you are already on a statin and adding ezetimibe, the ACC/AHA statin safety guidelines recommend checking transaminases at baseline and again six to twelve weeks after any dose change [12].

Creatine kinase (CK) is not routinely required before ezetimibe alone, but if you have reported prior muscle symptoms on a statin, your provider may check baseline CK before combining agents. A TSH may be ordered if hypothyroidism is suspected, since untreated hypothyroidism is a secondary cause of hyperlipidemia and can falsely suggest statin resistance [13].

Pregnancy testing is appropriate for women of reproductive age, as ezetimibe is FDA Category X in combination with a statin due to statins' teratogenic potential. Ezetimibe alone is Category C, meaning animal studies have shown adverse fetal effects but adequate human studies are lacking [6].

Telehealth Providers in Tennessee Prescribing Zetia

Tennessee supports a strong telehealth infrastructure for cardiovascular risk management. Several national platforms with Tennessee licensure regularly prescribe ezetimibe:

Telehealth prescribing for lipid-lowering agents requires the same clinical standard of care as in-person visits. The Tennessee Medical Association's telehealth guidelines state that "the standard of care does not change because a service is delivered via telemedicine" [9]. That means your telehealth provider must review your labs, calculate your cardiovascular risk, document the indication, and follow up appropriately.

The HealthRX clinical team uses a four-step telehealth triage framework for ezetimibe candidates in Tennessee:

1. Lab verification. Confirm a fasting LDL-C above the patient's risk-stratified goal (for example, LDL <70 mg/dL for very high-risk, <100 mg/dL for high-risk per ACC/AHA 2019 [5]).
2. Statin status check. Confirm the patient is on maximally tolerated statin therapy or has a documented statin intolerance with at least two statin trials per AHA guidelines [5].
3. ASCVD risk calculation. The 10-year Pooled Cohort Equations score drives the intensity of therapy. Patients with established ASCVD or score above 7.5% qualify for ezetimibe consideration [5].
4. Insurance pre-check. Run a real-time pharmacy benefit check before the visit ends to flag plans requiring prior authorization, saving the patient 48 to 72 hours.

Most HealthRX telehealth visits for ezetimibe in Tennessee are completed in 20 to 30 minutes. The prescription is transmitted electronically to the patient's pharmacy of choice at visit end.

Prior Authorization for Zetia in Tennessee: What You Need

Prior authorization (PA) is the most common barrier to getting ezetimibe covered by Tennessee commercial plans. BlueCross BlueShield of Tennessee, Cigna Tennessee, Aetna, and UnitedHealthcare Tennessee all list ezetimibe as a Tier 2 or Tier 3 drug with step-therapy requirements on most formularies as of the 2025 plan year.

Standard PA documentation requirements in Tennessee include: a current fasting lipid panel showing LDL-C above the plan's threshold; documentation of at least one (often two) statin trials with doses and durations; evidence that the statin was maximally tolerated or caused adverse effects such as myopathy or elevated transaminases; and the prescriber's ICD-10 code (E78.00 for pure hypercholesterolemia, I25.10 for atherosclerotic heart disease without angina).

The Tennessee Department of Commerce and Insurance requires commercial insurers to respond to standard PA requests within three business days and urgent PA requests within 24 hours under Tenn. Code Ann. 56-32-126 [14]. If your PA is denied, Tennessee law gives you the right to an external independent review, which must be completed within 45 days for standard appeals or 72 hours for expedited reviews [14].

Patients whose PA is denied on first submission frequently succeed on appeal when the prescriber submits a peer-to-peer review call. Data from the Kaiser Family Foundation show that about 35% of PA denials are overturned on first-level appeal when the physician participates directly [15].

TennCare (Tennessee Medicaid) does not cover ezetimibe for hyperlipidemia as a standalone indication. TennCare's Preferred Drug List includes ezetimibe only for patients with homozygous familial hypercholesterolemia or as an adjunct in type 2 diabetes management. If you are a TennCare enrollee seeking ezetimibe for primary hyperlipidemia, a medical necessity exception request submitted by your prescriber is the primary avenue, though approval rates are low without a familial hypercholesterolemia diagnosis supported by genetic testing or a Dutch Lipid Clinic Network score above 6 [16].

Cost and Pharmacy Options for Ezetimibe in Tennessee

Generic ezetimibe is inexpensive without insurance. GoodRx pricing at major Tennessee pharmacies shows cash prices ranging from $15 to $28 per month for a 30-tablet supply of 10 mg generic ezetimibe as of early 2025. Walmart's $4 generic program does not include ezetimibe, but Publix Pharmacy in Tennessee offers a free generic drug program that has historically included ezetimibe; confirm directly with your local Publix pharmacy as this list updates annually.

Brand-name Zetia costs approximately $320, $380 per month without insurance. Merck's patient assistance program, available at merck.com/patient-assistance-program, can reduce or eliminate this cost for patients meeting income criteria (generally household income at or below 400% of the federal poverty level) [17].

Mail-order pharmacies (90-day supplies) further reduce costs. A 90-day supply of generic ezetimibe at OptumRx or CVS Caremark typically runs $30, $55 for patients with commercial insurance coverage, and $40, $70 cash price.

503A compounding pharmacies licensed in Tennessee can prepare ezetimibe in alternative dose forms (for example, as a powder for patients with tablet-swallowing difficulties). The Tennessee Board of Pharmacy licenses 503A facilities, and compounded ezetimibe is not FDA-approved, so insurance will not cover it. The clinical utility of compounded ezetimibe is narrow because the standard 10 mg tablet is the only dose studied in outcomes trials [4].

Transferring a Zetia Prescription to Tennessee

If you have an existing ezetimibe prescription from another state and move to Tennessee, or if you temporarily need your prescription filled at a Tennessee pharmacy, the transfer process is straightforward. Tennessee law permits retail pharmacies to accept transferred prescriptions from other states for non-controlled medications, provided the receiving pharmacist contacts the originating pharmacy to verify the prescription and the prescription has remaining refills [18].

Transfers between chain locations (for example, CVS to CVS, or Walgreens to Walgreens) are handled internally and typically complete within a few hours. Cross-chain transfers require a pharmacist-to-pharmacist call and may take up to one business day.

If your prescription was written by a provider not licensed in Tennessee and has no refills remaining, you need a new prescription from a Tennessee-licensed prescriber. A telehealth visit is the fastest route in that situation, often resulting in a new electronic prescription within the same day.

Mail-order prescriptions through national PBMs (Express Scripts, CVS Caremark, Optum Rx) do not require state transfer; they fill nationally and ship to any Tennessee address with standard delivery in two to five business days.

What Happens If Ezetimibe Is Not Enough?

Ezetimibe added to a maximally tolerated statin reduces LDL-C by roughly 24% combined in most patients [2]. If your LDL-C remains above goal after at least six weeks on combined statin-ezetimibe therapy, the ACC/AHA 2022 Prevention Guideline supports escalating to a PCSK9 inhibitor (evolocumab or alirocumab) for very high-risk patients whose LDL-C stays above 70 mg/dL [19].

The FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by 59% from baseline on top of statin therapy and reduced the composite cardiovascular endpoint by 15% (HR 0.85 to 95% CI 0.79, 0.92, P<0.001) [20]. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab similarly reduced major adverse cardiovascular events by 15% (HR 0.85 to 95% CI 0.78, 0.93, P<0.001) [21]. PCSK9 inhibitors require separate prior authorization and are substantially more expensive, averaging $500, $700 per month before insurer negotiation.

Bempedoic acid (Nexletol) is an oral alternative for statin-intolerant patients who cannot tolerate ezetimibe side effects. The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced major adverse cardiovascular events by 13% (HR 0.87 to 95% CI 0.79, 0.96, P<0.004) in statin-intolerant patients [22]. Tennessee commercial plans vary on formulary placement of bempedoic acid; some list it as Tier 3 with step-therapy through ezetimibe.

Inclisiran (Leqvio), a small interfering RNA PCSK9 inhibitor given as a subcutaneous injection every six months, received FDA approval in December 2021 and represents an option for patients with adherence concerns about daily oral therapy [23]. The ORION-10 trial (N=1,561) showed inclisiran lowered LDL-C by 52.3% at day 510 (P<0.001) [24].

Monitoring After Starting Ezetimibe in Tennessee

A fasting lipid panel four to twelve weeks after starting ezetimibe confirms the LDL-C response. The ACC/AHA statin and lipid management guideline recommends repeat lipid assessment at six to twelve weeks for any new lipid-lowering agent initiation [5]. If the response is adequate and the patient is tolerating the drug, annual lipid panels are generally sufficient for ongoing monitoring.

Ezetimibe does not require liver function monitoring beyond what is already indicated for concurrent statin use. Post-marketing data submitted to the FDA show no causal link between ezetimibe monotherapy and clinically significant hepatotoxicity [6]. Myopathy attributable to ezetimibe alone is rare; the IMPROVE-IT trial reported myopathy rates below 0.1% in both ezetimibe and placebo arms [4].

Report any new muscle pain, weakness, or dark urine to your prescriber promptly, as these could indicate statin-induced myopathy that is sometimes misattributed to ezetimibe when the two drugs are prescribed together.